RAPT - RAPT Therapeutics Inc Stock Price, Fair Value and News

$1.06-0.01 (-0.93%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RAPT Price Action

Last 7 days

-32.5%

Last 30 days

-35.4%

Last 90 days

-53.9%

Trailing 12 Months

-92.2%

RAPT RSI Chart

RAPT Valuation

Market Cap

37.1M

Price/Earnings (Trailing)

-0.34

Price/Sales (Trailing)

25.41

EV/EBITDA

-0.01

Price/Free Cashflow

-0.37

RAPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RAPT Fundamentals

RAPT Revenue

Revenue (TTM)

1.5M

RAPT Earnings

Earnings (TTM)

-107.5M

Earnings Growth (Yr)

41.25%

Earnings Growth (Qtr)

33.37%

RAPT Profitability

EBT Margin

-4532.02%

Return on Equity

-112.55%

Return on Assets

-99.1%

Free Cashflow Yield

-272.03%

RAPT Investor Care

Shares Dilution (1Y)

1.63%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	3.2M	3.2M	2.3M	1.5M
2021	5.3M	4.9M	4.4M	3.8M
2020	0	0	0	5.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About RAPT Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Dr. Brian Russell Wong M.D., Ph.D.
WEBSITE	rapt.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	122

RAPT Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for RAPT Therapeutics Inc? What does RAPT stand for in stocks?

RAPT is the stock ticker symbol of RAPT Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RAPT Therapeutics Inc (RAPT)?

As of Wed Nov 20 2024, market cap of RAPT Therapeutics Inc is 37.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RAPT stock?

You can check RAPT's fair value in chart for subscribers.

Is RAPT Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RAPT is over valued or under valued. Whether RAPT Therapeutics Inc is cheap or expensive depends on the assumptions which impact RAPT Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RAPT.

What is RAPT Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, RAPT's PE ratio (Price to Earnings) is -0.34 and Price to Sales (PS) ratio is 25.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RAPT PE ratio will change depending on the future growth rate expectations of investors.